A warranty model backed by insurance aims to unlock access to high-cost therapies
As the biotech sector races to develop transformative but expensive therapies, a new financial tool has emerged to mitigate the risks of new treatments falling short of expectations.
Drug warranties are providing pharmaceutical manufacturers with a novel way to manage financial, reputational, and clinical risk.
Global insurance broking and risk management firm Marsh teamed up with Octaviant Financial in 2023 to create a specialized drug warranty program that’s among the first of its kind in the US life sciences sector.
As the market evolves, the program’s approach may shape future reimbursement models and redefine how payers evaluate risk in high-cost therapies. Marsh and Octaviant are now looking to expand the drug warranty program to territories outside the US, particularly sin…